Share-Based Compensation (Tables)

6 Months Ended

Dec. 31, 2017

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2017 is as follows:

	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2017		8.0		$	24.67
Options granted		—		$	—
Less:
Options exercised		(0.5	)	$	23.39
Options canceled or expired		(0.1	)	$	26.60
Options outstanding at December 31, 2017		7.4		$	24.75
Options exercisable at December 31, 2017		7.4		$	24.75

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2017 is as follows:

	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2017		2.0		$	33.02
RSUs granted		1.1		$	32.64
Less:
RSUs vested		(0.7	)	$	34.97
RSUs canceled		(0.1	)	$	27.40
RSUs outstanding at December 31, 2017		2.3		$	32.77

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

	Three months ended				Six months ended
	December 31,				December 31,
	2017		2016		2017		2016
Cost of molecular diagnostic testing	$	0.2	$	0.3	$	0.3	$	0.4
Cost of pharmaceutical and clinical services		0.0		0.0		0.1		0.1
Research and development expense		1.2		1.4		2.1		3.0
Selling, general, and administrative expense		5.5		5.7		10.8		11.7
Total share-based compensation expense	$	6.9	$	7.4	$	13.3	$	15.2